Letter to the EditorIncreased prevalence of Toxoplasma gondii seropositivity in patients with treatment-resistant schizophrenia
Section snippets
Conflict of interest
The authors declare no conflict of interest.
Contributors
Suzana Vlatkovic, Marina Sagud, Dubravka Svob Strac and Nela Pivac designed the study. Suzana Vlatkovic, Marina Sagud, Maja Zivkovic, Maja Vilibic, Bjanka Vuksan-Cusa and Alma Mihaljevic-Peles participated in collection of demographic and clinical data. Suzana Vlatković performed the rating scales. Mario Sviben determined the TG IgG antibodies. Dubravka Svob Strac performed statistical analysis. Marina Sagud, Dubravka Svob Strac and Suzana Vlatković wrote the manuscript. All authors
Funding
The investigation was a part of a project “Predictors of treatment response in schizophrenia”, BM1.45, sponsored by the University of Zagreb, Croatia.
References (10)
- et al.
Differential cognitive performances between schizophrenic responders and nonresponders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses
Psychiatry Res.
(2013) - et al.
Toxoplasma gondii infection in schizophrenia and associated clinical features
Psychiatry Res.
(2016) - et al.
Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation
Psychiatry Res.
(2012) - et al.
The role of ethnicity in treatment refractory schizophrenia
Compr. Psychiatry
(2013) - et al.
Inverse association between urbanicity and treatment resistance in schizophrenia
Schizophr. Res.
(2016)
Cited by (12)
Association between schizophrenia and Toxoplasma gondii infection in Algeria
2020, Psychiatry ResearchCitation Excerpt :It is not yet elucidated whether some of these metabolic changes are induced by the parasite via secreted effectors but antipsychotic medications by targeting similar pathways may influence T. gondii persistence in the CNS. Additional evidence of a possible interference between T. gondii and antipsychotic medications is supported by the observation of increased T. gondii seroprevalence in individuals with treatment-resistant forms of schizophrenia (Vlatkovic et al., 2018) compared to treatment-responsive patients. Thus, an improved understanding of the relationship between T. gondii infection and the pathophysiology of schizophrenia could help in preventing this devastating disease by developing new pharmacological treatment approaches.
Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort
2018, Schizophrenia ResearchCitation Excerpt :Exposure to Toxoplasma has been associated with increased blood-brain barrier permeability in SZ subjects (Kannan et al., 2017) and with substantial and widespread immune activation including increased C reactive protein (Tomasik et al., 2016). From a clinical point of view, latent Toxoplasma infection has been associated with older age of SZ onset (Esshili et al., 2016), treatment resistance (Vlatkovic et al., 2017), more severe illness course (Celik et al., 2015) and lower functioning (Esshili et al., 2016). Latent Toxoplasma infection has been associated with negative symptoms in one study (Esshili et al., 2016), but not in one another (Karabulut et al., 2015).
Serologic evaluation of cytomegalovirus (CMV), Toxoplasma gondii and Brucella in schizophrenia patients
2023, Caspian Journal of Internal MedicineClinical and demographic features of acutely hospitalised schizophrenia patients according to Toxoplasma gondii serostatus
2023, European Journal of Translational and Clinical MedicineLatent infections, coronavirus disease 2019 and psychiatric disorders: The friend of my enemy
2022, Clinical and Translational Discovery
- 1
Equally contributing authors.